We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

54 hedge funds and large institutions have $2.21M invested in Outlook Therapeutics in 2026 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 6

139% more call options, than puts

Call options by funds: $79K | Put options by funds: $33K

14% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 14

2.04% more ownership

Funds ownership: 10.64% → 12.68% (+2%)

2% more funds holding

Funds holding: 53 → 54 (+1)

80% less capital invested

Capital invested by funds: $10.8M → $2.21M (-$8.57M)

Holders
54
Holders Change
+1
Holders Change %
+1.89%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
15
Reduced
6
Closed
14
Calls
$79K
Puts
$33K
Net Calls
+$46K
Net Calls Change
+$2.67M

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$1.8M
2
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$154K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$124K
4
WAM
Warberg Asset Management
Illinois
+$119K
5
Renaissance Technologies
Renaissance Technologies
New York
+$110K

Top Sellers

Rank Fund Capital Flow
1
SSA
Schonfeld Strategic Advisors
New York
-$3.86M
2
Marshall Wace
Marshall Wace
United Kingdom
-$472K
3
Millennium Management
Millennium Management
New York
-$260K
4
SC
Scotia Capital
Ontario, Canada
-$117K
5
LA
LVW Advisors
New York
-$76.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Raymond James Financial
26
Raymond James Financial
Florida
$5.57K +$11.7K +27,051 New
PNC Financial Services Group
27
PNC Financial Services Group
Pennsylvania
$5.15K +$4.32K +10,000 +67%
FCC
28
Flower City Capital
New York
$4.12K – – –
OC
29
Oppenheimer & Co
New York
$3.19K +$6.7K +15,500 New
TRCT
30
Tower Research Capital (TRC)
New York
$3.05K +$835 +1,932 +15%
SG
31
StoneX Group
New York
$2.7K +$5.67K +13,122 New
HI
32
Harbour Investments
Wisconsin
$2.53K +$930 +2,152 +21%
Goldman Sachs
33
Goldman Sachs
New York
$2.12K -$15.3K -35,507 -78%
Osaic Holdings
34
Osaic Holdings
Arizona
$1.53K -$722 -1,670 -19%
VGA
35
Vanguard Global Advisers
Pennsylvania
$1.42K +$2.98K +6,907 New
Morgan Stanley
36
Morgan Stanley
New York
$783 -$958 -2,218 -37%
FFO
37
Fortitude Family Office
Arizona
$526 +$920 +2,130 +502%
Jones Financial Companies
38
Jones Financial Companies
Missouri
$520 – – –
Wells Fargo
39
Wells Fargo
California
$510 – – –
Northwestern Mutual Wealth Management
40
Northwestern Mutual Wealth Management
Wisconsin
$472 +$74 +171 +8%
FDCDDQ
41
Federation des caisses Desjardins du Quebec
Quebec, Canada
$262 – – –
AA
42
Ancora Advisors
Ohio
$226 – – –
EWA
43
EverSource Wealth Advisors
Alabama
$143 – – –
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$63 – – –
Carson Wealth (CWM LLC)
45
Carson Wealth (CWM LLC)
Nebraska
$58 – – –
SS
46
SBI Securities
Japan
$46 +$5 +12 +6%
AAG
47
Armstrong Advisory Group
Massachusetts
$37 – – –
LFG
48
Larson Financial Group
Missouri
$21 – – –
PWMG
49
Prestige Wealth Management Group
New Jersey
$13 – – –
IA
50
IFP Advisors
Florida
$10 – – –
1
2
3

OTLK Hedge Fund Activity: Q1 2026 in Review

54 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2026, worth a combined $2.21M — down 80% from $10.8M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new OTLK positions and 14 closed out — a net gain of 2 holders — while 15 added to existing stakes and 6 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $1.8M. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $3.86M sold.

  • 54 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2026, up from 53 in Q4 2025.
  • Funds reported $2.21M of Outlook Therapeutics stock for Q1 2026, down 80% quarter-over-quarter.
  • 16 funds opened new Outlook Therapeutics positions in Q1 2026 and 14 closed out, a net change of +2 holders.
  • The largest Outlook Therapeutics buyer in Q1 2026 was Armistice Capital, an estimated $1.8M added.
  • The largest Outlook Therapeutics seller in Q1 2026 was Schonfeld Strategic Advisors, an estimated $3.86M sold.

Based on aggregated 13F filings for Q1 2026.